Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations.
Second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) dolutegravir (DTG), bictegravir (BIC) and cabotegravir (CAB) showed a high genetic barrier to resistance and limited cross-resistance with first generation INSTIs raltegravir (RAL) and elvitegravir (EVG). In this study, DTG, BIC and CAB demonstrated a comparable activity on a panel of INSTI resistant strains isolated from patients exposed to RAL, EVG and/or DTG, with a significantly reduced susceptibility only with the Q148H/K/R plus one-two additional INSTI mutations pathway.